Voices
Kohei Shitara, FGFR2
Kohei Shitara/X

Kohei Shitara: New Findings on FGFR2 Isoform Ratios and Prognosis in Gastric and GEJ Cancer

Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X about a paper he co-authored with colleagues published in ESMO Open:

“In a recent report, ESMO Open, we show that a high FGFR2-IIIc to IIIb isoform ratio in gastric/GEJ cancer is associated with poor prognosis, EMT, and progression. Further analysis of the bemarituzumab-treated tumor is needed.”

Title: FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer

Authors: T. Hashimoto, N. Iida, S. Kadowaki, A. Makiyama, N. Machida, N. Takahashi, S. Boku, T. Kudo, E. Oki, K. Ohtsubo, T. Kawakami, N. Okano, Y. Komatsu, S. Yuki, N. Sakamoto, T. Kuwata, R. Yamashita, M. Amisaki, T. Shibuki, M. Imai, T. Fujisawa, Y. Nakamura, H. Bando, K. Shitara, T. Yoshino

Read the Full Article on ESMO Open.

Kohei Shitara: New Findings on FGFR2 Isoform Ratios and Prognosis in Gastric and GEJ Cancer

More posts featuring Kohei Shitara.

A. Makiyama cancer E. Oki ESMO Open gastric cancer gastroesophageal junction cancer H. Bando K. Ohtsubo K. Shitara M. Amisaki M. Imai N. Iida N. Machida N. Okano N. Sakamoto N. Takahashi OncoDaily Oncology R. Yamashita S. Boku S. Kadowaki S. Yuki T. Fujisawa T. Hashimoto T. Kawakami T. Kudo T. Kuwata T. Shibuki T. Yoshino Y. Komatsu Y. Nakamura